QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

KURA

QT55Kura Oncology, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
9.93
+0.36+3.76%
OverviewShort InterestFilings
KURAQT55Kura Oncology, Inc.·NASDAQ
OverviewShort InterestFilings
9.93+3.76%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-3.35
Insider Own11.01%
Shs Outstand88.77M
Perf Week12.08%
Market Cap849.57MForward P/E-EPS next Y-2.65Insider Trans-0.02%Shs Float-Perf Month10.83%
Enterprise Value834.76MPEG0.07EPS next Q-0.91Inst Own-Short Float-Perf Quarter17.79%
Income-295140852.00P/S11.86EPS this Y-5.82%Inst Trans-Short Ratio-Perf Half Y-6.59%
Sales71.64MP/B7.86EPS next Y25.13%ROA-45.14%Short Interest-Perf YTD-4.43%
Book/sh1.22P/C-EPS next 5Y-ROE-141.95%52W High12.49 -20.50%Perf Year60.16%
Cash/sh6.54P/FCF-EPS past 3/5Y-ROIC-57.53%52W Low5.45 82.20%Perf 3Y-
Dividend Est.-EV/EBITDA-2.86Sales past 3/5Y-Gross Margin94.66%Volatility3.08% 3.90%Perf 5Y-
Dividend TTM-EV/Sales11.65EPS Y/Y TTM-65.84%Oper. Margin-443.54%ATR (14)0.53Perf 10Y-
Dividend Ex-Date-Quick Ratio6.14Sales Y/Y TTM31.48%Profit Margin-411.19%RSI (14)58.19Recom2.00
Dividend Gr. 3/5Y-Current Ratio6.15EPS Q/Q-25.76%SMA204.65%Beta1.58Target Price22.25
Payout0.00%Debt/Eq0.23Sales Q/Q28.57%SMA506.24%Rel Volume1.00Prev Close9.57
Employees192LT Debt/Eq0.11EarningsAug 06SMA2006.01%Avg Volume1.70MPrice9.93
IPO DateSep 16, 2015Option/ShortYes / YesEPS/Sales Surpr.5.68% -30.77%Net Debt/EBITDA0.05Volume1,699,962Change3.76%
Analyst Ratings
DateActionAnalystRatingTarget
Jun-15-26ReiteratedBernstein$24
Jun-04-26ReiteratedWells Fargo$24
Jun-04-26ReiteratedCLSA$24
May-28-26ReiteratedJefferiesBuy$24
May-28-26ReiteratedOppenheimerOutperform$24
Apr-14-26InitiatedLake StreetBuy$23
Mar-13-26ReiteratedUBSBuy$14 → $15
Jan-13-26ReiteratedLeerink PartnersOutperform$20
Nov-24-25ReiteratedBarclaysOverweight$28
Nov-14-25ReiteratedH.C. Wainwright$32 → $40
Latest News
Jun-15-26
Jun-15-2609:59AM
Citizens Reiterates Market Outperform on Kura Oncology, Maintains $24 Price TargetBenzinga
Jun-13-26
Jun-13-2601:30AM
Kura Oncology, Inc. (KURA) Presents at European Hematology Association (EHA) 2026 Congress - SlideshowSeekingAlpha
Jun-12-26
Jun-12-2607:02PM
Kura Oncology, Inc. (KURA) Discusses Long-Term Results of Ziftomenib Combination Therapies in Newly Diagnosed and Relapsed/Refractory AML TranscriptSeekingAlpha
Jun-11-26
Jun-11-2612:02PM
Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AMLYahoo
08:09AM
Kura Oncology And Kyowa Kirin Announce Long-Term Results From The Phase 1/2 KOMET-007 Single-Arm Trial Evaluating Ziftomenib In Combination With Intensive ChemotherapyBenzinga
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue716754
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A400
Gross Profit686754
Selling, General and Administrative Excl. Other12812077
Research and Development260251170
Other Operating Expense-200
Operating Income-318-304-193
Interest Expense022
Unusual Expense
———
Non-Operating Income (Expense)-25-27-23
Net Income Before Taxes-294-278-172
Income Taxes002
Consolidated Net Income-294-279-174
Net Income From Continuing Operations-294-279-174
Net Income-294-279-174
EPS (Recurring)-3.35-3.18-2.02
EPS (Basic, Before Extraordinaries)-3.35-3.18-2.02
EPS (Diluted)-3.35-3.18-2.02
EBITDA-293-276-169
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio12.4513.65—
Gross Margin95.77100.00100.00
Operating Margin-447.89-453.73-357.41
Net Margin-414.08-416.42-322.22
Shares Outstanding898886
Market Capitalization884914—
Operating Lease Expense
———
Insider Trading Volume
$10.35$9.62$8.89$8.16$7.43● Close Price0.00K174.50K349.01K523.51K698.01KUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Powl Brian T.Chief Commercial OfficerMay 21 '26Sale11.0010,000110,000173,614May 22 12:00 AM
FORD KATHLEENChief Operating OfficerMay 19 '26Sale9.082,25720,483153,560May 20 12:00 AM
Powl Brian T.Chief Commercial OfficerMay 19 '26Sale9.213393,122183,614May 20 12:00 AM
Bair Teresa BrophyChief Legal OfficerMay 18 '26Sale9.382,25621,160226,931May 20 12:00 AM
WILSON TROY EDWARDPresident and CEOMar 23 '26Option Exercise6.1512,20675,066435,456Mar 25 12:00 AM
Malley ThomasDirectorMar 18 '26Option Exercise3.1220,00062,40010,000Mar 20 12:00 AM
Bair Teresa BrophyChief Legal OfficerJan 27 '26Sale8.4611,20894,828226,931Jan 27 12:00 AM
Powl Brian T.Chief Commercial OfficerJan 27 '26Sale8.466,41454,266183,275Jan 27 12:00 AM
FORD KATHLEENChief Operating OfficerJan 27 '26Sale8.461,81315,339153,560Jan 27 12:00 AM
Leoni MollieChief Medical OfficerJan 27 '26Sale8.468,18069,209267,274Jan 27 12:00 AM
DOYLE THOMAS JAMESSVP, Finance & AccountingJan 27 '26Sale8.467,14260,427145,167Jan 27 12:00 AM
Burrows FrancisChief Scientific OfficerJan 27 '26Sale8.461,31111,09232,424Jan 27 12:00 AM
Burrows FrancisChief Scientific OfficerDec 18 '25Option Exercise4.8070,000336,00057,461Dec 19 12:00 AM
Burrows FrancisChief Scientific OfficerDec 18 '25Sale9.7823,726231,93133,735Dec 19 12:00 AM
Hasnain FaheemDirectorDec 09 '25Sale10.9810,000109,76423,983Dec 10 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR